The agreement grants Novavax an upfront cash payment of $500 million, milestone-based payments, and proceeds from the equity stake sale. This capital infusion will strengthen Novavax's balance sheet, providing a much-needed boost for the vaccine maker, which has faced challenges in bringing its COVID-19 vaccine to market on time.